Except for the effects of CREB3L1 mutations on sarcoma formation, the expression of CREB3L1 can also serve as a marker for the efficacy and survival prediction of doxorubicin based palliative chemotherapy for patients with advanced soft tissue sarcoma 91. This evidence concerns the gene CREB3L1 and soft tissue sarcoma.